ACE and hydrops fetalis: Although a variety of current therapies have been proven to benefit heart failure patients such as beta-blockers, ACE inhibitors, Aldactone, and Entresto, there are no drugs in development to specifically target abnormal bioenergetics in the creatine phosphate system and their adverse effects on cardiac muscle function in HF patients.